<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213196</url>
  </required_header>
  <id_info>
    <org_study_id>HSK21542-102</org_study_id>
    <nct_id>NCT04213196</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers</brief_title>
  <official_title>A Phase I Clinical Study Evaluating the Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, Phase I, single-dose escalation clinical trial conducted in Chinese
      healthy volunteers. The safety, tolerability, and PK of HSK21542 injection in healthy
      volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial
      design
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE/serious AE</measure>
    <time_frame>From screening up to 4 weeks</time_frame>
    <description>Adverse event/serious adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs: Systolic and Diastolic Blood Pressure</measure>
    <time_frame>From screening up to 4 weeks</time_frame>
    <description>Vital signs (Systolic and Diastolic Blood Pressure) will be collected in healthy volunteers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>-30 minutes before administration until 24 hours after administration</time_frame>
    <description>Cmax（a measure of the body's exposure to HSK21542）will be calculated in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve（AUC）</measure>
    <time_frame>-30 minutes before administration until 24 hours after administration</time_frame>
    <description>AUC（a measure of the body's exposure to HSK21542）will be calculated in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>-30 minutes before administration until 24 hours after administration</time_frame>
    <description>time to peak observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance</measure>
    <time_frame>-30 minutes before administration until 24 hours after administration</time_frame>
    <description>Total clearance</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>HSK21542 0.2 μg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers 0.2 μg/kg HSK21542</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK21542 0.5 μg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers 0.5 μg/kg HSK21542 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK21542 1 μg/kg （15min)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers 1 μg/kg HSK21542 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK21542 1 μg/kg （2min)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers 1 μg/kg HSK21542 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK21542 2 μg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers 2 μg/kg HSK21542 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK21542 5 μg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers 5 μg/kg HSK21542 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK21542 10 μg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers 10 μg/kg HSK21542 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK21542 20 μg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers 20 μg/kg HSK21542 or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.</description>
    <arm_group_label>HSK21542 0.2 μg/kg</arm_group_label>
    <other_name>HSK21542 0.2 μg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.</description>
    <arm_group_label>HSK21542 0.5 μg/kg</arm_group_label>
    <other_name>HSK21542 0.5 μg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.</description>
    <arm_group_label>HSK21542 1 μg/kg （15min)</arm_group_label>
    <other_name>HSK21542 1 μg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.</description>
    <arm_group_label>HSK21542 1 μg/kg （2min)</arm_group_label>
    <other_name>HSK21542 1 μg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>Intravenous injection 2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.</description>
    <arm_group_label>HSK21542 2 μg/kg</arm_group_label>
    <other_name>HSK21542 2 μg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>Intravenous injection 5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.</description>
    <arm_group_label>HSK21542 5 μg/kg</arm_group_label>
    <other_name>HSK21542 5 μg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>Intravenous injection 10 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.</description>
    <arm_group_label>HSK21542 10 μg/kg</arm_group_label>
    <other_name>HSK21542 10 μg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>Intravenous injection 20 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.</description>
    <arm_group_label>HSK21542 20 μg/kg</arm_group_label>
    <other_name>HSK21542 20 μg/kg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females aged 18-45 years old (inclusive) at screening;

          2. Male volunteers no less than 50 kg, or female volunteers no less than 45 kg, with body
             mass index [BMI] in the range of 18.0-27.0 kg/m2 (inclusive) at screening;

          3. Healthy volunteers, as assessed by the investigator based on past medical history,
             comprehensive physical examination, vital signs, and specified tests and examinations.

          4. Fully understand the nature, purpose, and potential benefits, inconveniences and risks
             of the trial. Understand the study procedure and voluntarily provide written informed
             consent.

          5. Able to communicate with the investigator and to follow all requirements of the study,
             and willing to be admitted into the phase I clinical facility.

        Exclusion Criteria:

          1. Volunteers with a positive urine nicotine test;

          2. Volunteers with drug abuse or dependence, or with a positive urine drugs of abuse
             test;

          3. Blood donation or loss of blood &gt; 450 mL within the past 3 months;

          4. Participation in any clinical trials within the past 3 months;

          5. Volunteers who plan to become pregnant within the next 6 months;

          6. Any other factors judged by the investigator to be unsuitable for participating in
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Yan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The Second Affiliated Hospital of Zhejiang University Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong-gang Lou, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The Second Affiliated Hospital of Zhejiang University Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shi-ping Ma, PhD</last_name>
    <phone>（021)50799069</phone>
    <email>masp@haisco.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping-an Yao, M.S</last_name>
    <phone>（028）67258864</phone>
    <email>yaopa@haisco.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Zöllner C, Mousa SA, Fischer O, Rittner HL, Shaqura M, Brack A, Shakibaei M, Binder W, Urban F, Stein C, Schäfer M. Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. J Clin Invest. 2008 Mar;118(3):1065-73. doi: 10.1172/JCI25911.</citation>
    <PMID>18246198</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>January 5, 2020</last_update_submitted>
  <last_update_submitted_qc>January 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

